Sanofi and Regeneron’s Dupixent (dupilumab) continues its march against a host of chronic inflammatory diseases, posting positive phase 3 data in children with eosinophilic esophagitis, a chronic inflammation of the esophagus associated with acid reflux, gastrointestinal problems, difficulty eating and failure to thrive.
Source: Drug Industry Daily